Cargando…
Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population
Severe Strongyloides stercoralis, such as hyperinfection syndrome, carries a high mortality risk. Even with appropriate treatment, patients may experience infectious complications and failure of therapy. Currently, there are no Food and Drug Administration–approved parenteral therapies available for...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990086/ https://www.ncbi.nlm.nih.gov/pubmed/29866667 http://dx.doi.org/10.1136/bcr-2017-223138 |
_version_ | 1783329554982502400 |
---|---|
author | Zeitler, Kristen Jariwala, Ripal Restrepo-Jaramillo, Ricardo Kapadia, Shyam Casanas, Beata Alrabaa, Sally Sriaroon, Chakrapol |
author_facet | Zeitler, Kristen Jariwala, Ripal Restrepo-Jaramillo, Ricardo Kapadia, Shyam Casanas, Beata Alrabaa, Sally Sriaroon, Chakrapol |
author_sort | Zeitler, Kristen |
collection | PubMed |
description | Severe Strongyloides stercoralis, such as hyperinfection syndrome, carries a high mortality risk. Even with appropriate treatment, patients may experience infectious complications and failure of therapy. Currently, there are no Food and Drug Administration–approved parenteral therapies available for treatment in patients who develop gastrointestinal complications from hyperinfection, including small bowel obstruction. A veterinary form of ivermectin is available as a subcutaneous injection, although current literature in humans is limited. We report on the successful treatment of two surviving immunocompromised patients with S. stercoralis hyperinfection syndrome after prompt recognition and initiation of veterinary subcutaneous ivermectin therapy. |
format | Online Article Text |
id | pubmed-5990086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-59900862018-06-08 Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population Zeitler, Kristen Jariwala, Ripal Restrepo-Jaramillo, Ricardo Kapadia, Shyam Casanas, Beata Alrabaa, Sally Sriaroon, Chakrapol BMJ Case Rep Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation) Severe Strongyloides stercoralis, such as hyperinfection syndrome, carries a high mortality risk. Even with appropriate treatment, patients may experience infectious complications and failure of therapy. Currently, there are no Food and Drug Administration–approved parenteral therapies available for treatment in patients who develop gastrointestinal complications from hyperinfection, including small bowel obstruction. A veterinary form of ivermectin is available as a subcutaneous injection, although current literature in humans is limited. We report on the successful treatment of two surviving immunocompromised patients with S. stercoralis hyperinfection syndrome after prompt recognition and initiation of veterinary subcutaneous ivermectin therapy. BMJ Publishing Group 2018-06-04 /pmc/articles/PMC5990086/ /pubmed/29866667 http://dx.doi.org/10.1136/bcr-2017-223138 Text en © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation) Zeitler, Kristen Jariwala, Ripal Restrepo-Jaramillo, Ricardo Kapadia, Shyam Casanas, Beata Alrabaa, Sally Sriaroon, Chakrapol Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population |
title | Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population |
title_full | Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population |
title_fullStr | Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population |
title_full_unstemmed | Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population |
title_short | Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population |
title_sort | successful use of subcutaneous ivermectin for the treatment of strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population |
topic | Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990086/ https://www.ncbi.nlm.nih.gov/pubmed/29866667 http://dx.doi.org/10.1136/bcr-2017-223138 |
work_keys_str_mv | AT zeitlerkristen successfuluseofsubcutaneousivermectinforthetreatmentofstrongyloidesstercoralishyperinfectioninthesettingofsmallbowelobstructionandparalyticileusintheimmunocompromisedpopulation AT jariwalaripal successfuluseofsubcutaneousivermectinforthetreatmentofstrongyloidesstercoralishyperinfectioninthesettingofsmallbowelobstructionandparalyticileusintheimmunocompromisedpopulation AT restrepojaramilloricardo successfuluseofsubcutaneousivermectinforthetreatmentofstrongyloidesstercoralishyperinfectioninthesettingofsmallbowelobstructionandparalyticileusintheimmunocompromisedpopulation AT kapadiashyam successfuluseofsubcutaneousivermectinforthetreatmentofstrongyloidesstercoralishyperinfectioninthesettingofsmallbowelobstructionandparalyticileusintheimmunocompromisedpopulation AT casanasbeata successfuluseofsubcutaneousivermectinforthetreatmentofstrongyloidesstercoralishyperinfectioninthesettingofsmallbowelobstructionandparalyticileusintheimmunocompromisedpopulation AT alrabaasally successfuluseofsubcutaneousivermectinforthetreatmentofstrongyloidesstercoralishyperinfectioninthesettingofsmallbowelobstructionandparalyticileusintheimmunocompromisedpopulation AT sriaroonchakrapol successfuluseofsubcutaneousivermectinforthetreatmentofstrongyloidesstercoralishyperinfectioninthesettingofsmallbowelobstructionandparalyticileusintheimmunocompromisedpopulation |